ProteinQure raises $11M in Series A funding, led by Tom Williams of Heron Rock Fund, to support its first clinical trial for PQ203 and advance pipeline programs.
ProteinQure raises $11M in Series A funding, led by Tom Williams of Heron Rock Fund, to support its first clinical trial for PQ203 and advance pipeline programs.
05/28/25, 3:00 PM
Location
torontoMoney raised
$11 million
Industry
therapeutics
biotechnology
health care
Round Type
series a
Investors
Kensington Capital, Golden Ventures, Heron Rock Fund, Tom Williams
ProteinQure, a Toronto-based biotechnology company, has closed $11M in Series A financing. The funding will support the initiation of its first clinical trial for PQ203 and advance additional pipeline programs in neurology and nephrology. The round was led by Tom Williams of Heron Rock Fund, with participation from Golden Ventures and Kensington Capital. This funding brings the total amount raised to $16M.
Company Info
Location
toronto, ontario, canada
Additional Info
ProteinQure is a biotechnology company developing computational peptide therapeutics. They focus on designing therapeutic peptides using a proprietary platform that combines machine learning, structural biology, and atomic-level simulations. Their innovations aim to enable tissue-specific delivery and access to novel target classes in various medical fields such as oncology and neurology. The company is advancing programs for challenges like triple-negative breast cancer.